Pelthos Therapeutics Announces First Patient Dosed In Phase 1b/2a Clinical Trial Evaluating CT2000 As Potential Treatment For Eye Pain

Pelthos Therapeutics Inc. (NYSE: PTHS) has announced that the first patient has been dosed in a Phase 1b/2a clinical trial for CT2000, which aims to treat both acute ocular pain and chronic ocular surface pain related to dry eye disease. CT2000 is a lead asset of Channel Therapeutics, a subsidiary of Pelthos, which is conducting the trial through its Australian operations.